These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
99 related articles for article (PubMed ID: 12032399)
1. Splanchnic extraction and clearance of tissue plasminogen activator (t-PA) after injection of recombinant t-PA (Actilyse) in resting healthy subjects is proportional to the arterial concentration. Jørgensen M; Tønnesen KH; Petersen KR; Jespersen J; Gram J; Vinberg N Blood Coagul Fibrinolysis; 2002 Jun; 13(4):331-8. PubMed ID: 12032399 [TBL] [Abstract][Full Text] [Related]
2. Mean transit times and the sites of synthesis and catabolism of tissue plasminogen activator and plasminogen activator inhibitor type 1 in young subjects. Jørgensen M; Petersen KR; Vinberg N; Jespersen J; Gram J; Tønnesen KH Blood Coagul Fibrinolysis; 2001 Dec; 12(8):643-50. PubMed ID: 11734664 [TBL] [Abstract][Full Text] [Related]
3. Liver blood flow as a major determinant of the clearance of recombinant human tissue-type plasminogen activator. de Boer A; Kluft C; Kroon JM; Kasper FJ; Schoemaker HC; Pruis J; Breimer DD; Soons PA; Emeis JJ; Cohen AF Thromb Haemost; 1992 Jan; 67(1):83-7. PubMed ID: 1615490 [TBL] [Abstract][Full Text] [Related]
4. Release of tissue-type plasminogen activator (t-PA) in the splanchnic circulation of the anaesthetised pig during high sympathetic tone. Björkman JA; Ilebekk A; Jern C Thromb Res; 2010 Mar; 125(3):e106-9. PubMed ID: 19931890 [TBL] [Abstract][Full Text] [Related]
5. The effect of submaximal exercise on fibrinolysis. Fras Z; Keber D; Chandler WL Blood Coagul Fibrinolysis; 2004 Apr; 15(3):227-34. PubMed ID: 15060418 [TBL] [Abstract][Full Text] [Related]
6. Comparative thrombolytic properties of tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (u-PA) and K1K2Pu (a t-PA/u-PA chimera) in a combined arterial and venous thrombosis model in the dog. Lu HR; Wu Z; Pauwels P; Lijnen HR; Collen D J Am Coll Cardiol; 1992 May; 19(6):1350-9. PubMed ID: 1342779 [TBL] [Abstract][Full Text] [Related]
7. No Influence of acute hypertriglyceridemia on plasma t-PA in healthy male volunteers. Kemme MJ; Burggraaf J; Schoemaker RC; Cohen AF Thromb Res; 2001 Jul; 103(1):9-16. PubMed ID: 11434941 [TBL] [Abstract][Full Text] [Related]
8. Interaction study between nifedipine and recombinant tissue-type plasminogen activator in healthy subjects. De Boer A; Kluft C; Kasper FJ; Kroon JM; Schoemaker HC; Breimer DD; Soons PA; Cohen AF Br J Clin Pharmacol; 1993 Aug; 36(2):99-104. PubMed ID: 8398589 [TBL] [Abstract][Full Text] [Related]
9. Effects of increased liver blood flow on the kinetics and dynamics of recombinant tissue-type plasminogen activator. van Griensven JM; Huisman LG; Stuurman T; Dooijewaard G; Kroon R; Schoemaker RC; Kluft K; Cohen AF Clin Pharmacol Ther; 1996 Nov; 60(5):504-11. PubMed ID: 8941023 [TBL] [Abstract][Full Text] [Related]
10. In vivo release of tissue-type plasminogen activator antigen from the human brachial artery. Dovjak N; Blinc A; Keber D Thromb Res; 2002 May; 106(4-5):249-55. PubMed ID: 12297133 [TBL] [Abstract][Full Text] [Related]
11. An experimental multiple-organ model for the study of regional net release/uptake rates of tissue-type plasminogen activator in the intact pig. Jern C; Seeman-Lodding H; Biber B; Winsö O; Jern S Thromb Haemost; 1997 Sep; 78(3):1150-6. PubMed ID: 9308769 [TBL] [Abstract][Full Text] [Related]
12. Thrombolytic and pharmacokinetic properties of chimeric tissue-type and urokinase-type plasminogen activators. Collen D; Lu HR; Lijnen HR; Nelles L; Stassen JM Circulation; 1991 Sep; 84(3):1216-34. PubMed ID: 1909220 [TBL] [Abstract][Full Text] [Related]
13. Dependence of fibrinolytic activity on the concentration of free rather than total tissue-type plasminogen activator in plasma after pharmacologic administration. Lucore CL; Fujii S; Sobel BE Circulation; 1989 Jun; 79(6):1204-13. PubMed ID: 2498004 [TBL] [Abstract][Full Text] [Related]
14. The pharmacokinetics of recombinant double-chain t-PA (duteplase): effects of bolus injection, infusions, and administration by weight in patients with myocardial infarction. Koster RW; Cohen AF; Kluft C; Kasper FJ; van der Wouw PA; Weatherley BC Clin Pharmacol Ther; 1991 Sep; 50(3):267-77. PubMed ID: 1914361 [TBL] [Abstract][Full Text] [Related]
15. Increase of tissue plasminogen activator in limbs during venous occlusion: a simple haemodynamic model. Keber D; Blinc A; Fettich J Thromb Haemost; 1990 Nov; 64(3):433-7. PubMed ID: 2128974 [TBL] [Abstract][Full Text] [Related]
16. Effects of liver blood flow on the pharmacokinetics of tissue-type plasminogen activator (alteplase) during thrombolysis in patients with acute myocardial infarction. van Griensven JM; Koster RW; Burggraaf J; Huisman LG; Kluft C; Kroon R; Schoemaker RC; Cohen AF Clin Pharmacol Ther; 1998 Jan; 63(1):39-47. PubMed ID: 9465840 [TBL] [Abstract][Full Text] [Related]
17. Bolus dose response characteristics of single chain urokinase plasminogen activator and tissue plasminogen activator in a dog model of arterial thrombosis. Badylak SF; Voytik S; Klabunde RE; Henkin J; Leski M Thromb Res; 1988 Nov; 52(4):295-312. PubMed ID: 3144052 [TBL] [Abstract][Full Text] [Related]
18. In vivo kinetics of 99mTc labeled recombinant tissue plasminogen activator in rabbits. Itoh K; Ieko M; Hiraguchi E; Kitayama H; Tsukamoto E Ann Nucl Med; 1994 Aug; 8(3):193-9. PubMed ID: 7811562 [TBL] [Abstract][Full Text] [Related]